Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2010-05-12
2011-11-01
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C536S023200, C536S023500
Reexamination Certificate
active
08048410
ABSTRACT:
A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
REFERENCES:
patent: 4826811 (1989-05-01), Sehgal et al.
patent: 4868116 (1989-09-01), Morgan et al.
patent: 5061688 (1991-10-01), Beissinger et al.
patent: 5339346 (1994-08-01), White
patent: 5438041 (1995-08-01), Zheng et al.
patent: 5449614 (1995-09-01), Danos et al.
patent: 5466668 (1995-11-01), Glaser et al.
patent: 5639625 (1997-06-01), Carson et al.
patent: 5661033 (1997-08-01), Ho et al.
patent: 5827824 (1998-10-01), Light et al.
patent: 5863760 (1999-01-01), Light et al.
patent: 5869230 (1999-02-01), Sukhatme
patent: 5916874 (1999-06-01), Fujiwara et al.
patent: 5919619 (1999-07-01), Tullis
patent: 5981225 (1999-11-01), Kochanek et al.
patent: 5985846 (1999-11-01), Kochanek et al.
patent: 5994132 (1999-11-01), Chamberlain et al.
patent: 6083750 (2000-07-01), Chamberlain et al.
patent: 6207455 (2001-03-01), Chang
patent: 6290949 (2001-09-01), French et al.
patent: 6328958 (2001-12-01), Amalfitano et al.
patent: 6334194 (2001-12-01), Hihara
patent: 6335011 (2002-01-01), Podsakoff et al.
patent: 6342214 (2002-01-01), Tryggvason et al.
patent: 6888047 (2005-05-01), Wu et al.
patent: 7160539 (2007-01-01), Munn et al.
patent: 7179459 (2007-02-01), Sehgal et al.
patent: 7481998 (2009-01-01), Sehgal et al.
patent: 7501114 (2009-03-01), Sehgal et al.
patent: 7687058 (2010-03-01), Sehgal et al.
patent: 2002/0068713 (2002-06-01), Rade et al.
patent: 2002/0193336 (2002-12-01), Elkins et al.
patent: 2004/0198683 (2004-10-01), Sehgal et al.
patent: 2007/0184027 (2007-08-01), Seghal et al.
patent: 96/06933 (1996-03-01), None
patent: 99/14346 (1999-03-01), None
patent: 00/46360 (2000-08-01), None
patent: 01/29058 (2001-04-01), None
Parks, et al., “Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors”, J. Viral. 70 (10): 8027-8034, Oct. 1999.
GenBank Acc. No. M26434, “Human hypoxanthine phosphoribosyltransferease (HPRT) gene, complete cds”, US Natl. Library of Med., Bethesda, MD, USA, Nov. 26, 2001.
Orkin, et al., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, US National Institutes of Health, Bethesda, MD, USA, Dec. 7, 1995.
Verma, et al., “Gene therapy—promises, problems and prospects”, Nature 389: 239-242,1997.
Rosenberg, et al., “Gene therapist, heal thyself”, Science 287: 1751,2000.
Zuckerbraun, B.S., “Vascular gene therapy: a reality of the 21st century”, Arch. Surg. 137: 854-861, Jul. 2002.
Esmon, C.T., “Protein C in sepsis”, Ann. Med. 34: 598-605, 2002.
Waugh, et al., “Local Overexpression of Thrombomodulin for In Vivo Prevention of Arterial Thrombosis in a Rabbit Model”, Circulation Research, vol. 84, No. 1, pp. 84-92, 1999.
Waugh, et al., “Thrombomodulin Overexpression to Limit Neointima Formation”, Circulation, vol. 102, No. 3, pp. 332-337, 2000.
Vassalli, et al., “Gene therapy for arterial thrombosis”, Cardiovascular Research, vol. 19, No. 6, pp. 459-459,1997.
Umana, et al., “Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination”, Nature Biotechnology, vol. 19, No. 6, pp. 582-585, 2001.
Wen, et al., “Human Thrombomodulin: Complete eDNA Sequence and Chromosome Localization of the Gene”, Biochemistry, vol. 26, pp. 4350-4357,1987.
Borroni, et al., “Peripheral Blood Abnormalities in Alzheimer Disease: Evidence for Early Endothelial Dysfunction”, Alzheimer Disease and Associated Disorders, vol. 16, No. 3, pp. 150-155,2002.
McKay, et al., “Gene Transfer Therapy in Vascular Disease”, Cardiovascular Drug Reviews, vol. 19, No. 3, pp. 245-262, 2001.
Ausbel, et al., (eds) Greene Publishing Associates, “Current Protocols in Molecular Biology”, Sections 9.10-9.14,1989.
Ng, et al., “Development of a FLP/fre System for Generating Helper-Dependent Adenoviral Vectors”, Molecular Therapy, vol. 3, No. 5, pp. 809-815, 2001.
Bledsoe, et al., “Cytokine production in motor neurons by poliovirus replicon vector gene delivery”, Nature Biotechnol., vol. 18. pp. 964-969, 2000.
Chen, et al., “Low-Dose Vaccinia Virus-Mediated Cytokine Gene Therapy of Glioma”, Journal of Immunotherapy, vol. D 24, pp. 46-57, 2001.
Chen, et al., “Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo”, Proc. Natl. Acad. Sci. USA, vol. 91, pp. 3054-3057, 1994.
Cui, et al., “Plasmid DNA-Entrapped Nanoparticles Engineered from Microemulsion Precursers: In Vitro and In Vivo Evaluation”, Bioconjugate Chern., vol. 13, pp. 1319-1327, 2002.
Curiel, “Strategies to Adapt Adenoviral Vectors for Targeted Delivery”, Annals New York Academy of Sciences, vol. 886, pp. 158-171, 1991.
Gossen, et al., “Transcriptional Activation by Tetracyclines in Mammalian Cells”, Science, vol, 268, pp. 1766-1769, 1995.
Gossen, et al., “Tight control of gene expression in mammalian cells by tetracycline-responsive promoters”, Proc. Natl. Acad. Sci. USA, vol. 89, pp. 5547-5551, 1992.
Fink, et al., “Gene Transfer to Neurons Using Herpes Simplex Virus-Based Vectors”, Annual Rev. Neurosci., vol. 19, pp. 265-287,1996.
Flotte, et al., “Gene Expression from Adeno-associated Virus Vectors in Airway Epithelial Cells”, Am. J. Respir. Cell. Mol. Biol., vol. 7, pp. 349-356,1992.
Green, et al., “A New Scalable Method for the Purification of Recombinant Adenovirus Vectors”, Human Gene Therapy, vol. 13, pp. 1921-1934,2002.
Haj-Ahmand, et al., “Development of a Helper-Independent Human Adenovirus Vector and Its Use in the Transfer of the Herpes Simplex Virus Thymidine Kinase Gene”, J. Virol., vol, 57., pp. 267-273, 1986.
Howell, et al., “High-Level Dystrophin Expression After Adenovirus-Mediated Dystrophin Minigene Transfer to Skeletal Muscle of Dystrophic Dogs: Prolongation of Expression with Immunosuppression”, Human Gene Therapy, vol. 9, pp. 629-634, 1998.
Kay, et al., “Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector”, Nature Genetics, vol. 24, pp. 257-261, 2000.
Kessler, et al., “Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein”, Proc. Natl. Acad. Sci. USA, vol. 96, pp. 14082-14087, 1996.
Kistner, et al., “Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice”, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 10933-10938, 1996.
Magari, et al., “Pharmacologic Control of a Humanized Gene Therapy System Implanted into Nude Mice”, J. Clin. Invest., vol. 100, pp. 173-206, 1997.
Miller, “Progress Toward Human Gene Therapy”, Blood, vol. 76, pp. 271-278,1990.
Muzyczka, et al., “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells”, Curro Topics in Micro. and Immunology, vol. 158, pp. 97-129,1990.
Naldni, et al., “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector”, Science, vol. 272, pp. 263-267, 1996.
No, et al., “Ecdysone-inducible gene expression in mammalian cells and transgenic mice”, Proc. Natl. Acad. Sci., USA, vol. 93, pp. 3346-3351, 1996.
Pruchnic, et al., “The Use of Adeno-Associated Virus to Circumvent the Maturation-Dependent Viral Transduction of Muscle Fibers”, Human Gene Therapy, vol. 11, pp. 52
Sehgal Lakshman R.
Wong Jonathan
Andrews & Kurth LLP
Biovec, LLC
Schnizer Richard
Wang Ping
LandOfFree
In vivo and ex vivo gene transfer into renal tissue using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with In vivo and ex vivo gene transfer into renal tissue using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In vivo and ex vivo gene transfer into renal tissue using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4301813